-

AUPH Stock News: Robbins LLP Investigates Aurinia Pharmaceuticals Inc. (AUPH) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws regarding the financial impact of its drug LUPKYNIS. Aurinia is a biopharmaceutical company that develops and commercializes therapies to treat diseases with unmet medical need in Japan and the People's Republic of China. LUPKYNIS is the Company's only product, which it offers for the treatment of adult patients with active lupus nephritis.

If you would like more information about our investigation of Aurinia Pharmaceuticals Inc.'s misconduct, click here.

What is this Case About: According to a complaint filed against Aurinia, throughout the class period, defendants failed to disclose that the Company was experiencing declining revenues and that the 2022 sales outlook for LUPKYNIS would fall short of expectations.

On February 28, 2022, Aurinia announced its financial results for the full quarter and full year ended December 31, 2021, including a year-over-year revenue decline and lower than expected sales outlook for 2022. On this news, Aurinia's stock fell $3.94 per share, or 24.26%, to close at $12.30 per share on February 28, 2022.

Next Steps: If you acquired shares of Aurinia Pharmaceuticals Inc. (AUPH) between May 7, 2021 and February 26, 2022, you have legal options. Conact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Aurinia Pharmaceuticals Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:AUPH

Release Summary
AUPH Stock News: Robbins LLP Investigates Aurinia Pharmaceuticals Inc. (AUPH) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

CPNG Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Coupang, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coupang, Inc. (NYSE: CPNG) securities between April 6, 2025 and December 16, 2025. Coupang describes itself as one of the fastest-growing technology and commerce companies in the world, providing retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Cou...

Did You Lose Money in SFM? Stockholders Who Incurred Significant Financial Loss in Sprouts Farmers Market, Inc. Should Contact Robbins LLP to Learn About Leading the SFM Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Sprouts Farmers Market, Inc. (NASDAQ: SFM) is a specialty grocery store chain that operates in the U.S. What is the class period? June 4, 2025 - October 29, 2025. What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Sprouts Farmers Market, Inc. during the class period because the Company allegedly misled investors regarding its growth potential. For...

MCTA Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Class Action Against Charming Medical, Limited

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025. The Company claims to “enhance[] the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.” For more information, submit a form, email attorney Aaron Dumas, Jr., or give...
Back to Newsroom